Physician profile
Edward Chambers
NPI 1942383179
$1,798.37
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $634 · 2021: $373 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $432.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $225.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $207.98 | 2019-2021 | |
| Welch Allyn | $199.04 | 2020 | |
| Pfizer INC. | $192.76 | 2019-2021 | |
| Lilly USA, LLC | $125.20 | 2019-2022 | |
| Bausch Health US, LLC | $59.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.55 | 2019-2022 | |
| Eisai INC. | $44.10 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $40.00 | 2019 | |
| Boston Scientific Corporation | $39.27 | 2020-2021 | |
| Allergan, INC. | $38.27 | 2019 | |
| Seqirus USA INC | $31.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.34 | 2019 | |
| Redhill Biopharma INC. | $18.90 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18.28 | 2019 | |
| Sanofi Pasteur INC. | $14.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2022 | |
| Adlon Therapeutics L.P. | $12.02 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.